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About this Paper 
Legislation introduced by two members of the District of Columbia 
Council on January 9, 2007 would require all girls to be vaccinated against 
the human papillomavirus (HPV), the primary cause of cervical cancer, by 
the time they enter the sixth grade, unless a parent or guardian specifically 
“opts out” of the mandate. A similar bill was introduced last week in 
Virginia, and Maryland and West Virginia are poised to consider legislation. 
To place the proposals in a broader context, this paper reviews some of the 
scientific, legal, ethical and financial issues surrounding the HPV vaccine 
and compulsory vaccinations. The paper is being issued through the Jacobs 
Institute of Women’s Health, which is affiliated with the School of Public 
Health and Health Services.
For more information about the HPV vaccine:
Alexandra Stewart, JD 
Assistant Research Professor 
Department of Health Policy 
School of Public Health and Health Services 
The George Washington University 
2021 K Street, N.W., Suite 800 
Washington, DC 20006 
202-530-2331  
E-mail: stewarta@gwu.edu 
About the Rapid Public Health Policy Response Project
The Rapid Public Health Policy Response Project of the School of 
Public Health and Health Services at The George Washington University 
provides data and other background information on breaking public 
health stories. The goal is to educate the public, policymakers, legislators, 
health care providers, the media and others in order to promote informed 
decisionmaking. The Public Health and Policy Group of Pfizer, Inc. 
provides support for this project.
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In June 2006, the federal Food and Drug Administration (FDA) approved the first vaccine 
to protect females, ages 9-26, against four strains of the human papillomavirus (HPV). Two 
of these strains (strains 16 and 18) cause about 70% of all cases of cervical cancer; the 
other two (strains 6 and 11) cause 90% of all genital warts. The Advisory Committee on 
Immunization Practices (ACIP), a part of the Centers for Disease Control and Prevention, 
now recommends immunizing all girls and young women.
“Our challenge now is to determine how best to bring this tremendous medical 
breakthrough to the greatest number of people,” says Alexandra Stewart, JD, Assistant 
Research Professor in the Department of Health Policy at GW’s School of Public Health 
and Health Services. “In the past, policymakers have effectively used school mandates to 
achieve almost universal vaccination. That strategy is again being seriously considered.” 
The Problem
HPV infection is the most common sexually-transmitted disease in the United States, 
present in more than three-quarters of all women by age 50. There are more than 100 
strains of the virus, about 30 of which cause some form of genital infection. While often 
asymptomatic, HPV was responsible for almost 500,000 new cases of cervical cancer and 
some 250,000 deaths around the world in 2005, mostly in developing countries, according 
to the World Health Organization. 
Cervical cancer is less common in the United States, where Pap smears, which can 
detect pre-cancerous cell changes and early-stage disease, are routine. Nonetheless, about 
10,000 new cases, and 3,700 deaths occur annually in this country, disproportionately 
affecting African-American and Hispanic women. Nationwide, 8.8 women per 100,000 are 
diagnosed with cervical cancer; in the District of Columbia, the incidence rate is 13.5 per 
100,000. Death rates in the District are more than double national averages.1  
The Medical Advance
The HPV vaccine—called Gardasil and manufactured by Merck—is administered in 
three doses (dose one, followed in two months by dose two, and four months later by dose 
three)—and is safe and effective. The studies on which FDA approval was based identified 
only minor pain at the injection site as a common side effect. While it does nothing to treat 
existing infection, the vaccine confers almost 100% protection against new infections of 
the target HPV strains. Studies to date have shown immunization to be effective for five 
years; a booster shot may eventually be required to sustain protection. Because the vaccine 
does not target all cervical cancer-causing strains of HPV, Pap smears will continue to be 
recommended to sexually active females.2 
The Advisory Committee on Immunization Practices now recommends that girls 
be routinely vaccinated against HPV at age 11 or 12 and that a catch-up vaccine be 
administered to females, ages 13 to 26, if they have not already been vaccinated. ACIP also 
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notes that the vaccine can be given to girls as young as 9. While its recommendations are 
not binding, they typically become the standard of care.3  
Protecting the Target Audience
Because HPV infection is a sexually transmitted disease, the use of the vaccine, and 
especially proposals to make its use mandatory, take on added complexity and controversy. 
Might parents hesitate to approve vaccinations for their children for fear of suggesting that 
it is acceptable to be sexually active? Might the stigma of sexually transmitted diseases lead 
women to avoid the vaccine? Will clinicians recommend it?
The research shows that young women are very interested in getting the HPV vaccine, 
and are particularly receptive when it has been recommended by their doctors.4 Likewise, 
parents educated about its value are generally willing to have their children vaccinated. And 
clinicians are inclined to offer the HPV vaccine in their practices, especially where it has the 
support of their professional associations. Both the American College of Obstetricians and 
Gynecologists and the American Academy of Pediatrics endorse the use of the vaccine by 
their members.5  
Experts emphasize the importance of creating immunization opportunities, especially 
given the challenge of reaching adolescents and the need to administer three doses within a 
short time period. Standards of preventive care are not well-established for this population 
and they tend to receive few well-child exams. Indeed, people in their teens and early 20s 
make fewer visits to physicians’ offices than at any other time in their lives and currently fail 
to receive at least one of the other vaccines recommended for them.6,7 Given the widespread 
prevalence of HPV, the goal of the vaccine is to confer immunity before a girl has initiated 
any sexual activity. With 26% of females having vaginal intercourse by age 15, and most 
becoming sexually active at some point in their teenage years, that means inoculating them 
young.8   
Should the Vaccine be Mandatory?
The HPV Vaccination Reporting Act of 2007, introduced to the D.C. Council on January 
9th, would require certification that a girl has received the HPV vaccine prior to her 
enrollment in sixth grade.9 Parents would be permitted to opt-out of the requirement on 
terms that have not yet been specified. California, Kentucky, Maryland, South Carolina, 
Virginia and West Virginia are also considering mandatory HPV vaccination. A similar 
proposal was defeated in Michigan last month. 
Studies show that state laws requiring immunization as a condition of enrollment in 
school increase the use of vaccines, reduce disease, lessen racial disparities in coverage 
and increase available funding.10 “Requiring HPV vaccination by law will almost certainly 
achieve more widespread protection against the disease than will policies that rely 
exclusively on persuasion and education,” writes one commentator.11 That does not mean 
there is a consensus that HPV vaccination should be mandatory. 
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State Vaccine Mandates: Vaccination requirements are established on a state-by-state 
basis; there are no federal mandates. The legal precedent for mandatory vaccinations is 
the 1907 decision in Jacobsen v Massachusetts, when the U.S. Supreme Court upheld a 
Massachusetts law requiring smallpox vaccinations for adults, declaring that “the police 
power of a State must be held to embrace, at least, such reasonable regulations... as will 
protect the public health and the public safety.”12  
The diphtheria/pertussis/tetanus, measles/mumps/rubella and polio vaccines are almost 
universally required for children entering school; laws covering haemophilius influenzae 
Type B, hepatitis B, and varicella (chicken pox) vaccines vary.13 Exemptions on medical 
grounds are permitted everywhere. Most states also allow religious exemptions, and 20 
provide “personal-belief” exemptions, which vary in their flexibility. States that offer personal 
belief exemptions, and those that make any exemptions easy to get, have higher rates of 
unvaccinated children. They also have higher disease rates – for example, the incidence of 
pertussis (whooping cough) is twice as high in states that allow personal belief exemptions, 
compared to those that offer only religious exemptions.14 
Despite the social movement of some force and visibility that has arisen in recent years 
to question the safety and value of vaccines, more than 95 percent of school-age American 
children ultimately receive the mandated immunizations.15 Contagious diseases have 
dropped dramatically as a direct result. A single example: an average of 500,000 children 
contracted measles in the years shortly before the vaccine was introduced; in 2000, there 
were 81 cases of measles.16 
The HPV Debate: The traditional basis for school immunization mandates is to protect 
school-age children and the community at large from communicable disease. Public 
health experts argue for requiring vaccinations because they provide protection not only 
to vaccinated individuals, but also to the community as a whole. “Herd immunity” occurs 
when enough people are protected against the disease to slow or halt person-to-person 
transmission, even to those who are not vaccinated because they slip through the cracks of 
the medical system or are exempt for medical, religious or personal reasons.
An additional argument for an HPV vaccine mandate tied to school enrollment is 
the absence of consistent venues for serving adolescents. In general, adolescents and 
young adults have poorer access to care than any other population in the United States. 
The National Adolescent Health Information Center says that “a significant minority [of 
adolescents]—including the uninsured, the poor, some racial/ethnic groups and adolescents 
with special risk factors—report having foregone needed care and having unmet health 
needs.”17 If the HPV vaccine remains voluntary, adolescents in medically underserved 
communities are less likely to receive it, and another health disparity may well emerge 
between those who have ready access to medical care and those who do not. 
But public health concerns must be weighed against bioethical considerations, which 
generally place paramount value on respect for individual liberties, autonomy and the need 
to obtain informed consent for medical treatment. 
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Where a disease is transmitted through casual contact or airborne droplets, and a third-
party—such as a child who is medically ineligible for the measles vaccine—is placed at 
increased risk because someone else refuses vaccination, the public health advantage of 
mandatory vaccines has generally held sway. But because HPV infection is transmitted only 
through sexual contact, it provokes more scrutiny from bioethicists and others who want to 
limit the intrusion of government into the lives of its people. Towards that goal, some have 
argued that compulsory vaccination is “unacceptably paternalistic.”18 
Other objections to an HPV mandate focus on parental rights and concerns about 
condoning sexual activity in adolescence.19 There are also deep sensitivities in communities 
of color about stereotyping their sexual behavior. In a Washington Post opinion piece, 
Courtland Milloy writes that the DC proposal to vaccinate girls in school is built on this 
notion: “After all, your daughter is 11 and probably black, so the assumption is she’ll be 
having unprotected sex in no time – but don’t take offense.”20 Milloy also raises the specter 
of the Tuskegee experiments, in which black men were deliberately left untreated for 
syphilis, as a reminder that when it comes to medical treatment, government intent has not 
always been benign. 
Paying the Costs 
At a price of $360 for the required three doses, the HPV vaccine is one of the most expensive 
on the market. Whether or not vaccination becomes mandatory around the country, cost 
issues will need to be addressed. 
Private insurance companies are likely to pay for it, because they typically base 
reimbursement decisions on the guidelines of the Advisory Committee on Immunization. 
All Medicaid-eligible children under 21 are covered for all ACIP-approved vaccines, as are 
American Indian and Alaska Native teens under 18, and adolescents under 18 enrolled in 
the State Children’s Health Insurance Program. Federally funded community health centers, 
which charge for services on a sliding scale, may be another affordable source of coverage. 
Many states have additional mechanisms to vaccinate children, either through public clinics 
or by providing free supplies to private providers.21 
Vaccine coverage for adults is more problematic. Under Medicaid, vaccines are an 
optional benefit determined at the state level. Some states choose to provide some or all 
adults with free or low-cost vaccines at public clinics and affordable coverage is sometimes 
available at community health centers. Additionally, Merck has said it will provide limited 
free HPV vaccine through its patient assistance program to women who meet eligibility 
requirements based on income.22 Nonetheless, these piecemeal approaches will miss many 
women, leaving them either to pay for the vaccines themselves, or go without potentially 
lifesaving protection. 
In Conclusion
The approval of the HPV vaccine represents a significant breakthrough for women’s 
health. Now, the challenge is to find the best way to immunize as many girls and women as 
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possible before they become infected with the virus that causes cervical cancer. That will 
require careful debate about the relative risks and benefits of policies that rely on voluntary 
compliance with public health recommendations, compared to policies that mandate 
vaccination as a condition of school enrollment. 
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Notes on Sources
Ü 1  The incidence data on cervical cancer are drawn from multiple sources, 
including the Kaiser Family Foundation’s background brief, “HPV, Cervical 
Cancer and the New Vaccine,” which provides electronic links to additional 
data sources; the World Health Organization’s Comprehensive Cervical 
Cancer Control (2006); the National Cancer Institute SEER Cancer 
Statistics; and the DC Department of Health’s Division of Cancer Control, 
where a chart comparing DC and U.S. cervical cancer incidence and 
mortality rates among black and white women is available. 
Ü 2  Information about approval of the HPV vaccine, the trials on which it was 
based, and safety and efficacy findings are available at the FDA’s Center for 
Biological Evaluation and Research (CBER). 
Ü 3  ACIP’s recommended immunization schedule for children from birth to 18, 
including HPV, is published in Morbidity and Mortality Weekly Report, January 
5, 2007.
Ü 4  Two articles by Gregory D. Zimet review research on the attitudes of young 
women, parents and clinicians towards the HPV vaccine: “Understanding and 
Overcoming Barriers to Human Papillomavirus Vaccine Acceptance” (Current 
Opinion in Obstetrics and Gynecology, 2006) and “Improving Adolescent 
Health: Focus on HPV Vaccine Acceptance” (Journal of Adolescent Health, 
2005). 
Ü 5  The American College of Obstetricians and Gynecologists released its 
HPV vaccine recommendations for its members in an August 8, 2006 press 
release. The American Academy of Pediatrics included the HPV vaccine in its 
recommended 2007 immunization schedule, issued January 2, 2007. 
Ü 6  See Sharon Humiston and Susan Rosenthal, “Challenges to Vaccinating 
Adolescents: Vaccine Implementation Issues,” (Pediatric Infectious Disease 
Journal, June 2005). 
Ü 7  “Adolescent Vaccination: Bridging from a Strong Childhood to a Healthy 
Adulthood,” published in 2005 by the National Foundation for Infectious 
Diseases, describes current challenges to reaching adolescents with vaccines, 
and strategies for overcoming them. 
Ü 8  Data on sexual activities were collected in the 2002 National Survey of 
Family Growth conducted by the CDC’s National Center for Health 
Statistics and published in “Sexual Behavior and Selected Health Measures: 
Men and Women 15–44 Years of Age, United States, 2002,” Ádvance Data 
from Vital and Health Statistics, No. 362, September 15, 2005.
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Ü 9  Bill B17-30 was introduced by Council members David A. Catania and Mary 
M. Cheh.
Ü 10  Walter Orenstein and Alan Hinman describe the “safety net” provided by 
school-based immunization in “The Immunization System in the United 
States—the Role of School Immunization Laws,” (Vaccine, 1999).
Ü 11  James Colgrove explores the debate in “The Ethics and Politics of 
Compulsory HPV Vaccination” (New England Journal of Medicine, 
December 7, 2006).
Ü 12  The Supreme Court established the right of states to mandate vaccinations 
in Jacobsen v. Massachusetts (197 U.S. 11, 25 S.Ct 358, 1905). Subsequent 
key decisions include Zucht v. King (260 US 174, 43 S.Ct. 24, 1922), which 
upheld the constitutionality of city ordinances excluding unvaccinated 
children from school and Maricopa County Health Department v. Harmon 
(156 Ariz. 161, 750 P.2nd 1364, 1987), which determined that an 
individual’s right to education did not trump the state’s right to require 
measles vaccination, even in the absence of an outbreak at a particular 
school.
Ü 13  James G. Hodge, Jr. reviews existing state laws concerning vaccinations in 
“School Vaccination Requirements: Legal and Social Perspectives” (National 
Conference of State Legislatures State Legislative Report, August 2002).
Ü 14  Saad Omer and colleagues review state exemption policies and their impact 
on vaccination rates in “Nonmedical Exemptions to School Immunization 
Requirements” (Journal of the American Medical Association, October 11, 
2006). An international perspective is provided by Daniela Almon and 
colleagues in “Compulsory Vaccination and Conscientious or Philosophical 
Exemptions: Past, Present and Future” (Lancet, February 4, 2006). State-
by-state descriptions of criteria for vaccine exemptions at the Institute for 
Vaccine Safety. 
Ü 15  In addition to noting the 95 percent vaccination rate, James G. Hodge, Jr. 
describes historic and contemporary objections to mandatory vaccination in 
“School Vaccination Requirements: Legal and Social Perspectives” (National 
Conference of State Legislatures State Legislative Report, August 2002).
Ü 16  A table comparing the average annual incidence, prior to the introduction of 
a vaccine, of 10 vaccine-preventable diseases with 2000 figures is available 
in Kevin M. Malone and Alan R. Hinman, “Vaccine Mandates: The Public 
Health Imperative and Individual Rights,” a chapter in Law in Public Health 
Practice (Oxford University Press, 2003).
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Ü 17  Background about adolescent health care is available in an Adolescent and 
School Health Fact Sheet, August 2005, prepared by the Association of 
State and Territorial Health Officials; at the National Adolescent Health 
Information Center at the University of California, San Francisco; and in the 
NAHIC publication America’s Adolescents: Are They Healthy? ( 2003), which 
is the source of the quote. 
Ü 18  James Colgrove, “The Ethics and Politics of Compulsory HPV Vaccination” 
(New England Journal of Medicine, December 7, 2006).
Ü 19  See, for example, the statement of the Family Research Council to the 
Advisory Committee on Immunization Practices, August 24, 2006.
Ü 20  Courtland Milloy, “District’s HPV Proposal Tinged With Ugly Assumptions” 
(Washington Post, January 10, 2007).
Ü 21  For a detailed discussions of vaccine financing mechanisms, see Gary L. 
Freed, Sarah J. Clark and Anne E. Cowan, “State-Level Perspectives on 
Immunization Policies, Practices, and Program Financing in the 1990s” 
(American Journal of Preventive Medicine, 2000).
Ü 22  Information about Merck’s patient assistance program is available online or 
by calling (800) 293-3881.
